Aetna under investigation after medical director said he never looked at patient records

The California Department of Insurance is now examining Aetna’s claims denial process after a former medical director for the insurer’s Southern California operations, Jay Ken Iinuma, MD, said under oath that he never looked at a patient’s health record when deciding whether to approve a deny a claim.

Iinuma said he was following Aetna’s training to review recommendations from nurses who had read the patient’s record, rather looking at the record himself. California Insurance Commissioner Dave Jones said his office has asked Aetna to provide more information about its clinical review process.

"If the health insurer is making decisions to deny coverage without a physician actually ever reviewing medical records, that's of significant concern to me as insurance commissioner in California -- and potentially a violation of law," he told CNN.

The information came out as part of Iinuma’s deposition in a lawsuit filed against Aetna by a college student with a rare immune disorder. 23-year-old Gillen Washington has accused Aetna of “almost killing him” by denying coverage for an infusion of intravenous immunoglobulin (IVIG) when he was 19, while the insurer countered that Washington ignored their request for new blood work before authorizing the treatments.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.